![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 10
Zeitschriftenartikel
Konecny, G. E.; Hendrickson, A. E. Wahner; Davidson, T. M.; Winterhoff, B. J.; Ma, S.; Mahner, S.; Sehouli, J.; Fasching, P. A.; Feisel-Schwickardi, G.; Poelcher, M.; Roman, L. D.; Rody, A.; Karlan, B. Y.; Mullany, S. A.; Chen, H.; Ray-Coquard, I. L.; Provencher, D. M.; Yachnin, A.; Cottu, P. H.; Glaspy, J. A.; Haluska, P. und Slamon, D. J.
(2021):
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
In: Gynecologic Oncology, Bd. 163, Nr. 3: S. 465-472
Ray-Coquard, I.; Trama, Annalisa; Seckl, M. J.; Fotopoulou, C.; Pautier, P.; Pignata, S.; Kristensen, G.; Mangili, G.; Falconer, H.; Massuger, L.; Sehouli, J.; Pujade-Lauraine, E.; Lorusso, D.; Amant, F.; Rokkones, E.; Vergote, I.; Ledermann, J. A. und Schubert-Fritschle, Gabriele
(Januar 2019):
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
In: European Journal of Surgical Oncology, Bd. 45, Nr. 1: S. 67-74
Ray-Coquard, I.; Pautier, P.; Pignata, S.; Perol, D.; Gonzalez-Martin, A.; Berger, R.; Fujiwara, K.; Vergote, I.; Colombo, N.; Maenpaa, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Alia, E. M. Guerra; Reinthaller, A.; Nagao, S.; Lefeuvre-Plesse, C.; Canzler, U.; Scambia, G.; Lortholary, A.; Marme, F.; Combe, P.; de Gregorio, N.; Rodrigues, M.; Buderath, P.; Dubot, C.; Burges, A.; You, B.; Pujade-Lauraine, E. und Harter, P.
(2019):
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
In: New England Journal of Medicine, Bd. 381, Nr. 25: S. 2416-2428
Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W. G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; Baert, T.; Belaroussi, I.; Dashora, A.; Olbrecht, S.; Planchamp, F.; Querleu, D.; Baert, T.; Banerjee, S.; Belaroussi, I.; Blecharz, P.; Bruchim, I.; Cibula, D.; Colombo, N.; Concin, N.; Davidson, B.; Dashora, A.; Devouassoux-Shisheboran, M.; du Bois, A.; Ferrero, A.; Glasspool, R.; Gonzalez-Martin, A.; Heinzelmann-Schwarz, V.; Joly, F.; Kim, J. W.; Kridelka, F.; Ledermann, J.; Lorusso, D.; Mahner, S.; McCluggage, W. G.; McNeish, I.; Mikami, M.; Mirza, M. R.; Morice, P.; Nicum, S.; Olbrecht, S.; O'Donnell, D. M.; Pautier, P.; Planchamp, F.; Pignata, S.; Querleu, D.; Ray-Coquard, I.; Rodolakis, A.; Sehouli, J.; Selcukbiricik, F.; Sessa, C.; Singh, N.; Tan, D. S. P.; Timmerman, D.; Tognon, G.; van der Velden, J.; Vergote, I.; Witteveen, P. O. und Zeimet, A. G.
(2019):
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
In: Annals of Oncology, Bd. 30, Nr. 5: S. 672-705
Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W. G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; Baert, T.; Belaroussi, I.; Dashora, A.; Olbrecht, S.; Planchamp, F.; Querleu, D.; Banerjee, S.; Blecharz, P.; Bruchim, I.; Cibula, D.; Concin, N.; Davidson, B.; Devouassoux-Shisheboran, M.; Ferrero, A.; Glasspool, R.; Gonzalez-Martin, A.; Heinzelmann-Schwarz, V.; Joly, F.; Kim, J. W.; Kridelka, F.; Lorusso, D.; Mahner, S.; Mikami, M.; Mirza, M. R.; Nicum, S.; O'Donnell, D. M.; Pautier, P.; Rodolakis, A.; Sehouli, J.; Selcukbiricik, F.; Singh, N.; Tan, D. S. P.; Timmerman, D.; Tognon, G.; van der Velden, J.; Witteveen, P. O. und Zeimet, A. G.
(2019):
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
In: International Journal of Gynecological Cancer, Bd. 29, Nr. 4: S. 728-760
Scholtz, K.; Spies, C. D.; Moergeli, R.; Eckardt, R.; Dossow, V. von; Braun, S.; Sehouli, J.; Bahra, M.; Stief, C. G.; Wernecke, K. -D. und Schmidt, M.
(2018):
Risk factors for 30‐day complications after cancer surgery in geriatric patients: a secondary analysis.
In: Acta Anaesthesiologica Scandinavica, Bd. 62, Nr. 4: S. 451-463
Berek, J. S.; Matulonis, U. A.; Peen, U.; Ghatage, P.; Mahner, S.; Redondo, A.; Lesoin, A.; Colombo, N.; Vergote, I.; Rosengarten, O.; Ledermann, J.; Pineda, M.; Ellard, S.; Sehouli, J.; Gonzalez-Martin, A.; Berton-Rigaud, D.; Madry, R.; Reinthaller, A.; Hazard, S.; Guo, W. und Mirza, M. R.
(2018):
Safety and dose modification for patients receiving niraparib.
In: Annals of Oncology, Bd. 29, Nr. 8: S. 1784-1792
Sehouli, J.; Mahner, S.; Neunhoeffer, T.; Harter, P.; Gregorio, N. de; Fridrich, C.; Markmann, S.; Richter, R.; Potenberg, J.; Lorenz, R.; Schmidt, M.; Doering, G.; Belau, A.; Lueck, H. J.; Chekerov, R.; Du Bois, A. und Hilpert, F.
(2016):
Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial.
In: International Journal of Gynecological Cancer, Bd. 26: S. 2-3
Trillsch, F.; Mahner, S.; Hilpert, F.; Davies, L.; García-Martínez, E.; Kristensen, G.; Savarese, A.; Vuylsteke, P.; Los, M.; Zagouri, F.; Gladieff, L.; Sehouli, J.; Lee, C. Khoon; Gebski, V. und Pujade-Lauraine, E.
(2016):
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1733-1739
Trillsch, F.; Mahner, S.; Hilpert, F.; Davis, L.; Garcia, E.; Kristensen, G.; Savarese, A.; Vuylsteke, P.; Loos, M.; Zagouri, F.; Gladieff, L.; Sehouli, J.; Lee, C. K.; Gebski, V. und Pujade-Lauraine, E.
(2016):
Prognostic and predictive values of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.
In: Oncology Research and Treatment, Bd. 39: S. 93